| 0.5601 0.001 (0.11%) | 09-17 15:16 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.7  |
1-year : | 0.82 |
| Resists | First : | 0.6 |
Second : | 0.7 |
| Pivot price | 0.49 |
|||
| Supports | First : | 0.49 |
Second : | 0.41 |
| MAs | MA(5) : | 0.52 |
MA(20) : | 0.49 |
| MA(100) : | 0.66  |
MA(250) : | 1.43 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 88 |
D(3) : | 83.1 |
| RSI | RSI(14): 59.9 |
|||
| 52-week | High : | 3.32 | Low : | 0.41 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GRTS ] has closed below upper band by 1.3%. Bollinger Bands are 29.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.58 - 0.58 | 0.58 - 0.58 |
| Low: | 0.49 - 0.5 | 0.5 - 0.5 |
| Close: | 0.56 - 0.56 | 0.56 - 0.56 |
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Tue, 10 Sep 2024
Piper Sandler Maintains Gritstone Bio (GRTS) Overweight Recommendation - MSN
Tue, 13 Aug 2024
Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - Yahoo Finance
Tue, 30 Jul 2024
Class Action Lawsuit Against Gritstone Bio, Inc. (NASDAQ:GRTS) - TipRanks
Mon, 29 Jul 2024
GRITSTONE BIO, INC. (NASDAQ: GRTS) DEADLINE ALERT: - GlobeNewswire
Fri, 19 Jul 2024
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Gritstone bio, - GlobeNewswire
Fri, 12 Jul 2024
Lost Money on Gritstone bio, Inc.(GRTS)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 118 (M) |
| Held by Insiders | 1.1544e+008 (%) |
| Held by Institutions | 1.9 (%) |
| Shares Short | 7,850 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.2923e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -2 % |
| Return on Assets (ttm) | 995.4 % |
| Return on Equity (ttm) | -46.8 % |
| Qtrly Rev. Growth | 1.461e+007 % |
| Gross Profit (p.s.) | -107.96 |
| Sales Per Share | -412.13 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -111 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 1.45 |
| Dividend | 0 |
| Forward Dividend | 6.93e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|